Protalix to trial nerve gas treatment

The drug will probably only have to undergo Phase I trials.

Protalix (NYSE Amex: PLX) held a presentation for investors today, in which it reported that a Phase I (safety) trial for a drug it had developed for treating the effects o nerve gas would begin in the current quarter. Drugs for treating effects of ABC (atomic, biological, and chemical weapons) sometimes undergo only the safety test before their sale to customers, usually governments, is approved, because of the difficulty in finding ABC-affected patients for efficacy trials. This trial is therefore likely to be the last the company will have to carry out before its starts to sell the product.

The company also reported that the results of a trial of its treatment for Gaucher's disease showed that it was superior to the corresponding drug produced by Genzyme in penetration to the target cells.

Protalix also has in its pipeline of products a drug for the treatment of Fabry disease, and a treatment for arthritis.

Investment house HalmanAldubi began coverage of Protalix today with an unusually positive report. The investment house sees potential upside of over 100% in the company. Protalix's market cap is currently $540 million, HalmanAldubi's target price of $15 reflects a value of $1.3 billion. The report said that the share price did not reflect the added value of Protalix's technology platform, and called Protalix "the next Teva."

Published by Globes [online], Israel business news - www.globes-online.com - on January 24, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters